Center for Respiratory Research, University College London, London.
J Thorac Oncol. 2011 Sep;6(9):1505-9. doi: 10.1097/JTO.0b013e318223c3fe.
Mediastinal lymphadenopathy in patients with an extrathoracic malignancy is a common clinical scenario. Invasive sampling of intrathoracic lymph nodes may be performed by mediastinoscopy or endoscopic ultrasound-guided fine needle aspiration. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an alternative to mediastinoscopy and endoscopic ultrasound in patients with lung cancer and sarcoidosis. The utility of EBUS-TBNA in patients with extrathoracic malignancy was evaluated.
Consecutive patients who were suspected to have intrathoracic lymph node metastases from an extrathoracic malignancy underwent EBUS-TBNA. When EBUS-TBNA did not provide a specific diagnosis, patients underwent mediastinoscopy or clinical follow-up of at least 6 months duration.
One hundred sixty-one patients meeting the inclusion criteria underwent EBUS-TBNA in five UK centers over a 3-year period. EBUS-TBNA diagnosed mediastinal or hilar metastases in 71 (44%) patients, new lung cancer in 20 (12%) patients, and sarcoidosis in 14 (9%) patients. The sensitivity, negative predictive value for malignancy, and overall accuracy for EBUS-TBNA were 87%, 73% and 88%, respectively. One hundred ten (68%) patients in the study had a final diagnosis of malignant intrathoracic lymphadenopathy.
Because of the high prevalence of alternative diagnoses, pathological evaluation is important in patients with extrathoracic malignancy and suspected mediastinal or hilar lymph node metastases. EBUS-TBNA is a safe and sensitive technique and may be considered a first-line investigation in these patients.
患有胸外恶性肿瘤的患者出现纵隔淋巴结病是一种常见的临床情况。可以通过纵隔镜或内镜超声引导下细针抽吸术对胸内淋巴结进行有创性取样。支气管内超声引导下经支气管针吸活检术(EBUS-TBNA)是肺癌和结节病患者替代纵隔镜和内镜超声的一种方法。评估了 EBUS-TBNA 在胸外恶性肿瘤患者中的应用。
连续疑似患有胸外恶性肿瘤纵隔淋巴结转移的患者接受了 EBUS-TBNA 检查。如果 EBUS-TBNA 未提供明确的诊断,患者接受纵隔镜检查或至少 6 个月的临床随访。
在 3 年期间,5 个英国中心的 161 名符合纳入标准的患者接受了 EBUS-TBNA 检查。EBUS-TBNA 在 71 名(44%)患者中诊断出纵隔或肺门转移,20 名(12%)患者中诊断出新的肺癌,14 名(9%)患者中诊断出结节病。EBUS-TBNA 的敏感性、恶性肿瘤的阴性预测值和总体准确性分别为 87%、73%和 88%。研究中有 110 名(68%)患者最终诊断为恶性纵隔淋巴结病。
由于替代诊断的高患病率,病理评估对于患有胸外恶性肿瘤和疑似纵隔或肺门淋巴结转移的患者非常重要。EBUS-TBNA 是一种安全且敏感的技术,可考虑作为这些患者的一线检查方法。